Phathom Pharmaceuticals, Inc. Receivables

Receivables of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Receivables growth rates and interactive chart. Accounts receivable (AR) is the balance of money due to a firm for goods or services delivered or used but not yet paid for by customers. Accounts receivables are listed on the balance sheet as a current asset. AR is any amount of money owed by customers for purchases made on credit. When a company makes a sale, it records revenues and a corresponding balance in accounts receivable. When an invoice is paid, the accounts payable account is reduced and cash is received. Receivables should grow in-line with revenue over time, if they are growing much faster, a company might be booking revenue too aggressively.


Highlights and Quick Summary

Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Receivables of Phathom Pharmaceuticals, Inc.

Most recent Receivablesof PHAT including historical data for past 10 years.

Interactive Chart of Receivables of Phathom Pharmaceuticals, Inc.


Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.